Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $8.1429.

Several brokerages have recently weighed in on HUMA. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Monday, January 5th. Benchmark lowered their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. UBS Group reissued a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Finally, Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st.

Humacyte Stock Performance

Shares of Humacyte stock opened at $1.03 on Friday. The firm’s fifty day simple moving average is $1.14 and its 200-day simple moving average is $1.55. Humacyte has a 12 month low of $0.91 and a 12 month high of $4.85. The stock has a market capitalization of $192.89 million, a price-to-earnings ratio of -4.48 and a beta of 1.93. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.92 million. As a group, equities analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Institutional Trading of Humacyte

Several hedge funds have recently made changes to their positions in the company. Lazari Capital Management Inc. acquired a new position in shares of Humacyte during the second quarter worth about $27,000. Truist Financial Corp acquired a new stake in Humacyte in the third quarter valued at about $28,000. Prudential Financial Inc. purchased a new stake in Humacyte in the 2nd quarter valued at approximately $28,000. Financial Advisors Network Inc. purchased a new stake in Humacyte in the 2nd quarter valued at approximately $28,000. Finally, Equitable Holdings Inc. acquired a new position in Humacyte during the 3rd quarter worth approximately $29,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.